Shark liver oil supplementation enriches endogenous plasmalogens and reduces markers of dyslipidemia and inflammation
Autor: | Adam Alexander T. Smith, Man K.S. Lee, Michelle Cinel, Bronwyn A. Kingwell, Sudip Paul, Paul J. Nestel, Kevin Culham, Natalie A. Mellett, Kaushala S. Jayawardana, Kevin A. Gunawan, Peter J. Meikle, Jacqueline M. Weir, Graeme I. Lancaster, Andrew J. Murphy |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Male genetic structures PE(P) alkenyl phosphatidylethanolamine immunometabolism 030204 cardiovascular system & hematology Biochemistry LPC(O) lysoalkylphosphatidylcholine chemistry.chemical_compound PC phosphatidylcholine 0302 clinical medicine Endocrinology lipid metabolism hsCRP high-sensitivity C-reactive protein Cross-Over Studies Middle Aged metabolic disease medicine.anatomical_structure diet and dietary lipids medicine.symptom Research Article Adult medicine.medical_specialty Plasmalogen Plasmalogens Shark liver oil Inflammation QD415-436 03 medical and health sciences Fish Oils Double-Blind Method Internal medicine White blood cell Lipidomics medicine Animals Humans Dyslipidemias Cholesterol business.industry Lipid metabolism Cell Biology SLO shark liver oil medicine.disease COH cholesterol TG(O) monoalkyl-diacylglycerol BH Benjamini-Hochberg PC(P) alkenyl phosphatidylcholine 030104 developmental biology chemistry PC(O) alkyl phosphatidylcholine Dietary Supplements Sharks lipidomics sense organs PE(O) alkyl phosphatidylethanolamine business Dyslipidemia Biomarkers |
Zdroj: | Journal of Lipid Research Journal of Lipid Research, Vol 62, Iss, Pp 100092-(2021) |
ISSN: | 1539-7262 0022-2275 |
Popis: | Plasmalogens are membrane glycerophospholipids with diverse biological functions. Reduced plasmalogen levels have been observed in metabolic diseases; hence, increasing their levels might be beneficial in ameliorating these conditions. Shark liver oil (SLO) is a rich source of alkylglycerols that can be metabolized into plasmalogens. This study was designed to evaluate the impact of SLO supplementation on endogenous plasmalogen levels in individuals with features of metabolic disease. In this randomized, double-blind, placebo-controlled cross-over study, the participants (10 overweight or obese males) received 4-g Alkyrol® (purified SLO) or placebo (methylcellulose) per day for 3 weeks followed by a 3-week washout phase and were then crossed over to 3 weeks of the alternate placebo/Alkyrol® treatment. SLO supplementation led to significant changes in plasma and circulatory white blood cell lipidomes, notably increased levels of plasmalogens and other ether lipids. In addition, SLO supplementation significantly decreased the plasma levels of total free cholesterol, triglycerides, and C-reactive protein. These findings suggest that SLO supplementation can enrich plasma and cellular plasmalogens and this enrichment may provide protection against obesity-related dyslipidemia and inflammation. |
Databáze: | OpenAIRE |
Externí odkaz: |